Collectively, our data provide evidence that LXN is a key positive regulator of adipocyte differentiation, and therapeutics targeting LXN could be effective in preventing obesity and its associated disorders in clinical settings. This evidence concerns the gene LXN and obesity due to melanocortin 4 receptor deficiency.